Vertero Unveils New Strategic Direction Focused on Breaking Barriers in Neurodegenerative Diseases
Formerly Axial Therapeutics, Vertero is rapidly advancing a novel approach to address peripheral drivers of challenging neurodegenerative diseases Lead candidate VT-5006 is a first-in-class small molecule designed to precisely engage a validated target in the GI wall to slow the progression of Parkinson's disease $20M Series D financing supports Vertero's near-term goals and plans for […]